Bristol-Myers Squibb’s (NYSE:BMY) Q3 2026 sales top estimates
Bristol-Myers Squibb reported Q3 2026 revenue of $13.07 billion, exceeding estimates by 2.9% and growing 6.9% year-on-year. Adjusted EPS of $1.35 beat estimates by 12.4%. The company raised full-year revenue guidance to $50 billion but lowered adjusted EPS guidance to $6.45. Operating margin decreased to 19.4% from 24.6% year-on-year.
How this was made
The 30-second read
Why it matters
The key trading tension is that revenue guidance increases while adjusted EPS guidance decreases, alongside a year-over-year operating margin drop.
Market read
A guidance update with explicit beat and cut details can drive near-term repricing of earnings expectations and valuation multiples for BMY.
What to watch
Traders may overreact to the EPS midpoint cut without considering whether the revenue guidance raise implies stronger demand or better pricing that could later offset margin headwinds.
Background
The piece summarizes Bristol-Myers Squibb’s Q3 2026 results versus S&P analysts’ consensus and the company’s updated full-year guidance.
Ticker impact
Bristol-Myers Squibb reported Q3 2026 revenue of $13.07B and adjusted EPS of $1.35, beating consensus, and lifted revenue guidance while cutting EPS guidance.
Likely modest upside bias on the beat and revenue guidance raise, offset by pressure from the adjusted EPS guidance cut and weaker operating margin.
The article provides both upside (revenue and EPS beats, revenue guidance up) and downside (adjusted EPS guidance down, operating margin down year over year), which typically produces a mixed market reaction rather than a one-direction repricing.
Market effects
Signals ongoing margin pressure in large-cap pharma even when top-line growth holds, which can influence read-across expectations for peers’ earnings quality.
Primarily US large-cap pharma sentiment; limited direct spillover beyond healthcare equities.
US-listed pharma results can affect global pharma risk appetite, but the article contains no cross-border policy or supply shocks.
Counterpoint
The operating margin decline could be temporary (mix, one-offs, or cost timing), so the EPS guidance cut may be conservative rather than a structural deterioration.
Key entities
- companyBristol-Myers Squibb
US-listed pharma company reporting Q3 2026 results and updating full-year revenue and adjusted EPS guidance.
